Rezvilutamide

Rezvilutamide (INNTooltip International Nonproprietary Name),^[1][2] sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer.^[3][4][5] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.^[3][5] The drug was developed by Jiangsu Hengrui Medicine.^[3] Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.

Rezvilutamide

Clinical data
Other names	SHR3680
Drug class	Nonsteroidal antiandrogen
Identifiers
IUPAC name 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number	1572045-62-5
PubChem CID	89995232
UNII	70FJN2AW22
CompTox Dashboard (EPA)	DTXSID001336581
Chemical and physical data
Formula	C22H20F3N3O4S
Molar mass	479.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1 Key:KRBMOYIWQCZVHA-INIZCTEOSA-N